Glucocorticoids increase the risk of preterm premature rupture of membranes possibly by inducing ITGA8 gene expression in the amnion

Okazaki, Yuka; Taniguchi, Kosuke; Miyamoto, Yoshitaka; Kinoshita, Shiori; Nakabayashi, Kazuhiko; Kaneko, Kayoko; Hamada, Hiromi; Murashima, Atsuko; Hata, Kenichiro

doi:10.1016/j.placenta.2022.07.012

Cited by 4 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In [2], the gene ITGA8 was discussed; see also [17]. However, this gene was not identified in our computation.…”

Section: Discussionmentioning

confidence: 99%

cg05883128 (DDX60) and NR3C2 (CD4 T-cells and B-cells) to Be the Genetic Roots of Systemic Lupus Erythematosus

Zhang

2024

Preprint

View full text Add to dashboard Cite

Motivation: Systemic lupus erythematosus (SLE) is an autoimmune disease and a long-term condition affecting many body parts. Autoimmune diseases are affecting more people for reasons unknown, and the causes of these diseases remain a mystery. Method: A newly introduced robust competing (risk) max-logistic regression classifier that can simultaneously perform subtype clustering and classification for disease diagnoses and predictions becomes a new hope to solve the mystery. We use this method in the study to discover critical DNA methylation CpG sites and genome genes, which lead to the highest accuracy and interpretability. Results: The DNA methylation CpG site cg05883128 (DDX60) and gene NR3C2 are essentially responsible for SLE development. They can lead to 100% prediction accuracy together with a miniature set of other CpG sites and genes, respectively. cg05883128 (DDX60) reveals the LSE mechanism affecting many body parts. NR3C2 in CD4 T cells and B cells behaves reversely, leading to the cause of LSE and explaining the mechanism of the autoimmune disease. Conclusions: This work represents a pioneering effort and intellectual discovery in applying the max-logistic competing risk factor model to identify critical genes for LSE, and the interpretability and reproducibility of the results across diverse populations suggest that the CpGs and DEGs identified can provide a comprehensive description of the transcriptomic features of SLE. The practical implications of this research include the potential for personalized risk assessment, precision diagnosis, and tailored treatment plans for patients.

show abstract

“…In [2], the gene ITGA8 was discussed; see also [17]. However, this gene was not identified in our computation.…”

Section: Discussionmentioning

confidence: 99%

cg05883128 (DDX60) and NR3C2 (CD4 T-cells and B-cells) to Be the Genetic Roots of Systemic Lupus Erythematosus

Zhang

2024

Preprint

View full text Add to dashboard Cite

show abstract

“…The use of PDN during pregnancy has been found to increase the risk of premature delivery and, consequently, lower birth weight in pregnant women with RA. However, disease activity can negatively influence birth weight independently, likely through immune-mediated mechanisms [63].…”

Section: The Drawbacks Of Glucocorticosteroids In Treating Inflammato...mentioning

confidence: 99%

The dichotomy of glucocorticosteroid treatment in immuneinflammatory rheumatic diseases: an evidence-based perspective and insights from clinical practice

Hysa,

Vojinovic,

Gotelli

et al. 2023

Reumatologia

View full text Add to dashboard Cite

ObjectivesGlucocorticosteroids (GCs) are the most used anti-inflammatory and immunosuppressive drugs due to their effectiveness in managing pain and disease modification in many immune-inflammatory rheumatic diseases (IRDs). However, their use is limited because of adverse effects (AEs).Material and methodsThe authors analyzed recent studies, including randomized controlled trials (RCTs), observational, translational studies and systematic reviews, providing an in-depth viewpoint on the benefits and drawbacks of GC use in rheumatology.ResultsGlucocorticosteroids are essential in managing life-threatening autoimmune diseases and a cornerstone in many IRDs given their swift onset of action, necessary in flares. Several RCTs and meta-analyses have demonstrated that when administered over a long time and on a low-dose basis, GC can slow the radiographic progression in early rheumatoid arthritis (RA) patients by at least 50%, satisfying the conventional definition of a disease-modifying anti-rheumatic drug (DMARD). In the context of RA treatment, the use of modified-release prednisone formulations at night may offer the option of respecting circadian rhythms of both inflammatory response and HPA activation, thereby enabling low-dose GC administration to mitigate nocturnal inflammation and prolonged morning fatigue and joint stiffness. Long-term GC use should be individualized based on patient characteristics and minimized due to their potential AEs. Their chronic use, especially at medium/high dosages, might cause irreversible organ damage due to the burden of metabolic systemic effects and increased risk of infections. Many international guidelines recommend tapering/withdrawal of GCs in sustained remission. Treat-to-target (T2T) strategies are critical in setting targets for disease activity and reducing/discontinuing GCs once control is achieved.ConclusionsGlucocorticosteroids’ use in treating IRDs should be judicious, focused on minimizing use, tapering and discontinuing treatment, when possible, to improve long-term safety. Glucocorticosteroids remain part of many therapeutic regimens, particularly at low doses, and elderly RA patients, especially with associated chronic comorbidities, may benefit from long-term low-dose GC treatment. A personalized GC therapy is essential for optimal long-term outcomes.

show abstract

Calcineurin inhibitors in the treatment of systemic lupus erythematosus during pregnancy: A narrative review with emphasis on efficacy and safety

Jiang,

Tao,

Chen

et al. 2024

European Journal of Obstetrics & Gynecology and Reproductiv

View full text Add to dashboard Cite

Glucocorticoids increase the risk of preterm premature rupture of membranes possibly by inducing ITGA8 gene expression in the amnion

Cited by 4 publications

References 58 publications

cg05883128 (DDX60) and NR3C2 (CD4 T-cells and B-cells) to Be the Genetic Roots of Systemic Lupus Erythematosus

cg05883128 (DDX60) and NR3C2 (CD4 T-cells and B-cells) to Be the Genetic Roots of Systemic Lupus Erythematosus

The dichotomy of glucocorticosteroid treatment in immuneinflammatory rheumatic diseases: an evidence-based perspective and insights from clinical practice

Calcineurin inhibitors in the treatment of systemic lupus erythematosus during pregnancy: A narrative review with emphasis on efficacy and safety

Contact Info

Product

Resources

About